Fellows: Apply by 2/19 for the 2026 Paul Carbone, MD Fellowship Award, a research grant for senior oncology or hematology fellows that aims to develop & promote excellence in #clinicaltrials. Learn more: bit.ly/ea-carbone #cancerresearch

EA1241, led by Dr. Joseph Sparano of The Mount Sinai Hospital, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: bit.ly/EA1241

The nomination period is now open for the 2026 @eaonc.bsky.social Young Investigator Award! 🩺 This honor recognizes the scientific achievements of early-career investigators. Learn more & nominate a colleague by 2/19: bit.ly/ea-yia #mentorship #CancerResearch #ClinicalTrials

#Cancer #survivorship is up—but sustained research funding and equitable access to screening & treatment are key to continued progress. Learn more via ABC News: bit.ly/3NvFTv0 #CancerPolicy #CancerResearch

EA is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below. 📅Feb 4 | 4 PM ET 🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD 🔗https://bit.ly/EA1241webinar

DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau

“This is a great time to be in hashtag#oncology” — and also a time to rebuild how we support hashtag#science, access, & policy, says Dr. Otis Brawley, chair of our Social Determinants of Health Working Group. Catch his reflections in The Cancer Letter: bit.ly/4pgVzPX #SciencePolicy #SDOH

#FindingsFriday: Don’t miss the newest round-up of recently presented findings from ECOG-ACRIN Cancer Research Group & PrECOG Cancer Research Group #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/3YI9raZ #BreastCancer #Leukemia #Lymphoma

What happens when #ResearchFunding slows? A new analysis looks at stalled studies, delayed discoveries, and the challenges researchers face navigating uncertainty. Read more: bit.ly/44FKmRI #NIH

ICYMI: Watch Joseph A. Sparano, MD, FACP discuss initial findings from a public-private partnership between ECOG-ACRIN & Caris Life Sciences to improve recurrence risk assessment in early-stage #BreastCancer using #ArtificialIntelligence. Video via MedPage Today: bit.ly/48R3uNN #bcsm #AI #SABCS25

Support for collaborative, federally funded #CancerResearch remains essential. The NCI Director Dr. Tony Letai shares his perspective on sustaining this work in a conversation with The Cancer Letter. Read the interview: bit.ly/3Mzqnhd

ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools (@eaonc.bsky.social) https://cancerletter.com/clinical-roundup/20251212_6a/

Attending #SABCS25 this week? View this helpful guide to @eaonc.bsky.social research at the meeting, including data from an exciting TAILORx correlative science initiative. More: bit.ly/4iTDohN #BreastCancer #bcsm

New analysis of 10 ECOG-ACRIN Cancer Research Group trials shows that for Black #AML patients, survival advantage typically linked to certain mutations (like NPM1) doesn’t hold—highlighting a need to rethink how genetic risk factors are applied across racial groups. More: bit.ly/4pqT92h #ASH25

Attending #ASH25 this weekend? Don't miss the initial results from the myeloMATCH #PrecisionMedicine trial. More info on these exciting updates can be found here: dctd.cancer.gov/about/news-e...

#FindingsFriday: A new analysis of E3805/CHAARTED by Abhishek Tripathi, MD & colleagues shows long-term outcomes for men with metastatic #ProstateCancer may be tied to PSA levels early in treatment. Could offer hope and better planning. More: bit.ly/4oL80n7

At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma

The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more: dctd.cancer.gov/about/news-e... @swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP

On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma

#FindingsFriday: New insights from the CHAARTED trial, presented at #ASTRO25 - the APUC-6 signature (six androgen production/uptake & conversion genes) may help stratify metastatic #ProstateCancer & refine treatment response. Learn more: bit.ly/43SaV5t #PrecisionMedicine

ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch

#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa

The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S

After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...

DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch @swog.org

The Fall 2025 Group Meeting session recordings are now available on the Attendee Hub Website. Simply log in with your first name, last name, and the email address you used during registration ➡️ cvent.me/EvkYal #EAOnc

Phase 3 #ClinicalTrial EA8231 is now enrolling! This study is exploring a new treatment approach for patients with treatment-refractory locally-advanced or metastatic #UrothelialCancer. Learn more: bit.ly/ea8231-study... #TargetedTherapy

Day 2 of the #EAOnc Fall 2025 Group Meeting is underway! Let us know which sessions you are heading to today. And don’t miss our General Session at 5:30 PM! 🩺🩻📈

Thank you to the exceptional presenters and panelists who helped make the Fall 2025 Comis #TranslationalScience Symposium a success: Drs. Jon Steingrimsson, @rhubbbstat.bsky.social, Paul Catalano, Walter Witschey, @jordanberlin5.bsky.social, & Mary Lou Smith!

The Comis #TranslationalScience Symposium continues with talks by Dr. Paul Catalano of @danafarber.bsky.social @hsph.harvard.edu & Dr. Walter Witschey @pennmedicine.bsky.social. #AI #imaging

First up: talks from Dr. Jon Steingrimsson & Dr. @rhubbbstat.bsky.social, both of @brownbiostatistics.bsky.social, on #AI, #MachineLearning, & #RealWorldData in cancer #ClinicalTrials. More to come!

Group Co-Chair Dr. Mitch Schnall of @pennmedicine.bsky.social kicks off the Fall 2025 Robert L. Comis Translational Science Symposium, focused on #AI, #RealWorldData, and alternative approaches to phase 2 and 3 therapeutic questions. #EAOnc

The Robert L. Comis, MD Translational Science Symposium on Approaches Using #AI and Other Electronic Methods in #ClinicalTrials is underway. Join us in Salon E, 5th Floor! #EAOnc #CancerResearch

Congratulations to the Fall 2025 Edith Peterson Mitchell, MD Travel Scholars! #CancerResearch #ClinicalTrials #EAOnc

Congratulations to the early-career researchers selected to present at our annual Young Investigator Symposium! 🩻🩺📈#EAOnc

#Immunotherapy after surgery shows potential in preventing spread of aggressive skin cancer. STAMP (EA6174) results at #ESMO25 by Dr. Janice Mehnert of NYU Langone’s Perlmutter Cancer Center. Largest study to date to evaluate pembrolizumab as adjuvant therapy for #MerkelCellCarcinoma bit.ly/4hgQrJg

The #EAOnc Fall 2025 Group Meeting officially begins today! Looking forward to seeing you in Philadelphia. Check in at the registration desk on the 5th floor before heading to your first session. 🩺🩻📈

You may be eligible to participate in a #PancreaticCancer study, EA2192/APOLLO, for patients with #PancreaticCancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more: bit.ly/apollo-trial #pancsm

Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration. Learn more: bit.ly/4pRWiZy

We congratulate Dr. Anthony Letai on his appointment as NCI Director. His deep scientific expertise & reputation as a collaborative leader make him an excellent choice to drive progress against #cancer. We look forward to working with him! #CancerResearch #ClinicalTrials

Today is #WorldCancerResearchDay! Catch up on the latest @eaonc.bsky.social research highlights from our August newsletter here ➡️https://bit.ly/aug25research #EAOnc #CancerResearch

Today is the 2025 Rally for Medical Research! #RallyForNIH unites patients, survivors, researchers & advocates urging Congress to make National Institutes of Health funding a national priority. Join us in calling for sustained, robust NIH support. Important info➡️ rallyformedicalresearch.org

#NIH research is the basis for countless treatments and cures for patients battling life-threatening and chronic conditions. Join today’s #RallyMedRes & urge Congress to support robust, sustained funding for NIH. Tools & resources here: rallyformedicalresearch.org #FundNIH

ICYMI: Check out our round-up of recently published @eaonc.bsky.social research results. More here ➡️ bit.ly/aug25research #EAOnc

September is #ProstateCancerAwarenessMonth 💙. This month, we’re spotlighting EA8191/INDICATE, a #ClinicalTrial treating #ProstateCancer that has come back after surgery with apalutamide and targeted radiation based on PET imaging. More here: bit.ly/indicate-trial

More good news from Washington: Last week the House Labor-HHS Subcommittee advanced its FY26 spending bill, increasing both NCI & NIH funding and rejecting the proposed cuts. Thank you for working to prioritize #CancerResearch, patients, and survivors. Read more: bit.ly/4n3sYNN

In our August newsletter, the co-chairs spotlight an open letter to Congress from the National Clinical Trials Network Cooperative Group Chairs, detailing its significant contributions to patient welfare. Read their editorial and the full letter here: bit.ly/41x0VO5 #CancerResearch #ClinicalTrials

The EA3211 clinical study is testing a potential new treatment for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: bit.ly/ea3211-study #hncsm

Submit an Abstract for the 2025 Young Investigator Symposium by Thursday, 9/11! 🩻 We are now accepting research abstracts from early-career investigators interested in presenting your research as part of the upcoming Fall 2025 Group Meeting. More: bit.ly/yis-fall25 #EAOnc